63 avsnitt • Längd: 30 min • Veckovis: Onsdag
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.
Subscribe now and be part of the conversation that’s shaping the future of biotechnology.
Get ready for an immersive experience into the world of biotech with The BioHub.
The podcast The BioHub: The Top Voices in Biotech is created by Max Brennan - Biotech HeadHunter. The podcast and the artwork on this page are embedded on this page using the public podcast feed (RSS).
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Dr. Claudia Zylberberg — a pioneering force in cell and gene therapy and the founder of Akron Biotech.
Claudia has spent her career shaping the future of biologics manufacturing, building Akron into a key player in the CGT ecosystem, and championing the development of global standards for advanced therapies. She’s a scientist, an entrepreneur, and an advocate for innovation, quality, and access in one of the most complex areas of biotech.
From founding startups to influencing international policy, Claudia brings a wealth of experience and insight to the table — and I can’t wait to get into it.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
On this episode of The BioHub, I’m joined by Uwe Schoenbeck, Partner at Canaan and one of the most respected names in early-stage biotech.
After more than a decade leading external science and innovation at Pfizer, Uwe made the jump to venture capital, joining Canaan in 2023. With a background spanning big pharma, startups, and science itself—he’s uniquely positioned to see what’s coming next.
In this episode, we talk about the shift from pharma to VC, what founders get wrong when pitching, and the traits that separate the good companies from the great ones.
Enjoy and stay tuned.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have David Happel, CEO of Sagimet Biosciences
Listen to hear how they've been doing.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Gwen Acton, CEO of Vivo Group and an expert in leadership development for scientists, engineers, and biotech professionals.
Gwen has had a fascinating career—she earned a PhD from MIT, was a faculty member at Harvard, ran operations at the Whitehead Institute during the Human Genome Project, and has helped thousands of technical experts become stronger leaders.
Now, she’s adding “author” to her resume with a brand-new book on leadership, and today, we’re diving into why leadership is so crucial in biotech, how it’s evolved, and what inspired her to write it.
Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Today we're joined by David De Graaf, CEO of Co-Founder of Reverb TherapeuticsDavid has an incredible background, with positions at companies such as AstraZeneca, Pfizer, Apple Tree Partners & Boehringer Ingelheim as well being at the helm of multiple successful biotechs. In this episode, we dive into his journey, building out seed stage biotech's from scratch as well as the Canadian Biotech scene
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Judy Chou, CEO of AltruBio—one of the mostexciting biotech companies out there, especially after closing the largest Series B in biotech over the last four years.
Judy has an incredible background, having led global biotechat Bayer, held leadership roles at Pfizer, and served as research faculty at Harvard. Now, as the CEO of AltruBio, she’s driving the company’s mission to develop first-in-class immune modulators for autoimmune and inflammatorydiseases.
In this episode, we dive into her journey, how AltruBio isthriving in a tough market, and what’s ahead for the company in 2024. Let’s get into it!
Enjoy and stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Aoife Brennan, CEO of Climb Bio—a company at the cutting edge of pioneering new approaches to cell and gene therapy.
Aoife is a seasoned biotech leader with a track record of driving innovation. Before joining Climb Bio, she was the CEO of Synlogic, where she led the company through critical clinical advancements in engineered probiotic medicines.
With a background in medicine and deep experience in biotech strategy, she has a unique perspective on bridging science and business to create transformative therapies.
In this episode, we talk about her journey, what makes Climb Bio’s approach different, and how she’s navigating leadership in an ever-evolving industry.
Enjoy and stay Tuned.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Shalabh Gupta, a seasoned leader in the biotech industry and the current Founder, Chairman & CEO of Unicycive Therapeutics. Shalabh's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of Globavir Biosciences and CEO, Founder, Chairman and of BioCycive.Now, at the helm of Unicycive Therapeutics, Unicycive who are focused on developing new treatment options for patients with renal diseases, as kidney disease remains a major global health concer.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Iain Kilty, CEO of Sitryx, a biotech pushing boundaries in immunology and inflammation.
Iain’s journey is fascinating—after 22 years at Pfizer, leading global drug discovery efforts, he transitioned into biotech, taking on the CSO role at Sitryx before stepping up as CEO. Now, he’s leading the charge as Sitryx enters the clinic, a huge milestone for any company.
In this episode, we dive into:
Enjoy and stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by John Mumm, CEO of Deka Biosciences—a company breaking new ground in cytokine therapies for cancer and inflammatory diseases.
John is a true veteran of biotech, with over 30 years of experience in immunotherapy research. He’s spent his career working to unlock the potential of IL-10 and cytokines, tackling one of drug development’s biggest challenges. After leadership roles at MedImmune, and ARMO BioSciences, he founded Deka to bring a fresh approach to cytokine-based treatments.
Today, we dive into John’s journey as a three-time biotech founder, the fast-moving progress at Deka, and why cytokines have been so tough to crack—until now. Plus, we get into mindset, motivation, and what it takes to build a company that lasts.
Enjoy and Stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Melissa Sherman, CEO of MOBILion Systems—a true trailblazer shaking up separation science.Melissa was employee number one and has since raised $120M, built a world-class team, and launched Mobi, a technology that’s transforming how we analyze molecules. Think of it like upgrading from an old film camera to the latest high-definition digital—faster, clearer, and game-changing for drug developers.We dive into her inspiring journey of building MOBILion from the ground up, creating a winning company culture, and why she believes this tech is the future of separation science.Enjoy and Stay Tuned.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Stella Vnook, CEO of Likarda.
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Patrick Alexandre, CEO of Crossject.
Listen to hear how they've been doing.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David Esposito, a seasoned leader in the biotech industry and the CEO of ONL Therapeutics. David's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as President and CEO of Armune Biosciences, VP Commercial Operations at Thermo Fisher, and Executive Director Commercial Strategy at Merck.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Glen Gowers, CEO and co-Founder of Basecamp Research.
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Simrit Parmar, Founder of Cellenkos.
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Angelos Stergiou, CEO of Sellas Life Sciences
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Michael Parini, CEO of Spur Therapeutics.
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Yang Liu, CEO & CSO of OncoC4.
Listen to hear how they've been doing.
The first of our little spin off and time at JPM!
Big announcements and exclusives! Here we have Adrian Rawcliffe, CEO of Adaptimmune.
Listen to hear how they've been doing.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We have a special guest—Michael Castagna, CEO of MannKind Corporation. Michael has over 25 years of experience in marketing, sales, and business development across both Fortune 500 companies and biotech startups.
Under his leadership, MannKind has grown into a major player in the field of endocrine and orphan lung diseases, bringing innovative therapies like Afrezza®, the only inhaled ultra-rapid-acting insulin, to market.
In this episode, Michael shares his journey, the challenges and triumphs of leading MannKind, and the future of the company’s groundbreaking technologies.
We also dive deep into his passion for turning around struggling companies and the lessons he’s learned from navigating the biotech landscape.
Enjoy and Stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We are thrilled to welcome Dr. Kevin Warner, Senior Vice President of Medical Affairs strategy and engagement at Heron Therapeutics.
Dr. Warner brings 2 decades of experience in clinical and infusion pharmacy, with a special focus on pharmacokinetics, pharmacodynamics, and antimicrobial stewardship. He has been instrumental in co-developing the VT-X7 intra-articular antibiotic irrigation therapy and has played a crucial role in numerous committees dedicated to improving patient care.
At Heron Therapeutics, Dr. Warner is at the forefront of enhancing recovery after surgery and developing innovative pharmaceutical products using their proprietary Biochronomer™ drug delivery platform. With his extensive background and dedication to advancing patient care, Dr. Warner is a true leader in the pharmaceutical industry.
We’re excited to dive into his journey, explore Heron’s groundbreaking work, and discuss the future of pharmaceutical innovation.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have Mark Mallon, CEO of George Medicines.
Mark is a global leader in the pharmaceutical industry with over 25 years of experience. His career includes 24 years at AstraZeneca, where he held several key executive positions, leading operations across the globe.
More recently, Mark has served as the CEO of NeoGenomics Laboratories and Ironwood Pharmaceuticals, driving transformation and growth in both roles. Now at George Medicines, Mark leads the development of innovative, combination therapies designed to optimize the treatment of cardiometabolic diseases.
In this episode, we’ll explore Mark’s journey to George Medicines, the company’s innovative approach to tackling cardiometabolic diseases, and the importance of addressing global health inequities.
Welcome to the show, Mark! Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We are joined today by Founder and CEO of Terran Biosciences. Sam is a trailblazer in the Neuroscience space.
We discuss a number of topics in this episode but have a lot of focus on recent FDA breakthroughs, upcoming plans with their lead drug TerXT.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We're joined by CEO and Founder, Jason Bock. Jason has been instrumental in the mAb space, and now making a move into the CAR-T space.
In this episode, Jason shares his career experience, the move from mAb to CAR-T, and how CTMC is playing their part in this.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We’re joined by Joe Payne, CEO and founder of Arcturus Therapeutics. Joe has been instrumental in pushing the boundaries of mRNA technology, leading Arcturus to develop one of the first self-amplifying mRNA COVID-19 vaccines and pioneering new treatments for diseases like cystic fibrosis.
In this episode, Joe shares his journey, the ground breaking work at Arcturus, and his vision for the future of RNA medicine.
Let’s dive in!
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m pleased to introduce Adrian Rawcliffe, CEO of Adaptimmune Therapeutics. With over 20 years of experience in the pharmaceutical and biotech industries, Adrian has led pivotal roles at GSK and now spearheads the development of breakthrough T-cell therapies at Adaptimmune, tackling some of the toughest challenges in cancer and beyond.
We’re excited to dive into Adrian’s journey, the advancements at Adaptimmune, and what the future holds for T-cell therapies. Welcome to the show, Adrian!
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of hosting Greg Kunst, CEO of Aurion Biotech. Greg is a seasoned leader in the biotech industry with a remarkable career spanning drug development, commercialization, and market access. At Aurion, Greg has driven the company to incredible heights, raising over $200 million and securing product approval in Japan for their groundbreaking cell therapy platform. Under his leadership, Aurion has grown rapidly, with operations expanding across the U.S. and Japan. In this episode, we’ll explore Greg’s journey from his extensive experience in the industry to taking the helm at Aurion, the innovative technologies driving their mission, and what the future holds for this cutting-edge biotech company. Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We’re thrilled to have Sophia Lugo, CEO and co-founder of Radar Therapeutics. Sophia’s journey from El Paso to leading Radar is truly inspiring. Her passion for medicine and public health drives her mission to bring representation and accessibility to mRNA therapies. Radar Therapeutics is pioneering precision-expressed mRNAs to target specific diseased cells, aiming to revolutionize treatments for conditions like cancer and rare diseases. Recently, Radar raised $13.4 million in seed funding to advance their groundbreaking work. In this episode, we’ll explore Sophia’s journey, the technology behind Radar, and the importance of health equity in medicine. Enjoy and stay tuned.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David-Alexandre "DA" Gros, a seasoned leader in the biotech industry and the current CEO & Director of Eledon Pharmaceuticals. DA's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO Imbria Pharmaceuticals, President and Chief Operating Officer of Neurocrine Biosciences, Chief Business and Principal Financial Officer at Alynlam Pharmaceuticals, Chief Strategy Officer and EVP, Strategy & Business Development at Sanofi, Principal, Healthcare Investment Banking at Centerview Partners & Vice President, Healthcare Investment Banking at Merrill Lynch. Now, at the helm of Eledon Pharmaceuticals, Eledon are focused on striving to both extend the functional life of transplanted organs and reduce side effects of current immunosuppressive treatments such as kidney toxicity, high blood pressure, and tremor. DA's deep expertise, from startups to larger pharmaceutical companies gives him a unique perspective on how to steer innovative science towards tangible clinical outcomes. We're excited to dive into his journey, the challenges and successes along the way, changing career lanes & the business development landscape.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.We are thrilled to have Charmaine Lykins, Commercial Strategy Advisor at MapLight Therapeutics, join us.
Charmaine brings over 25 years of extensive experience in the commercial sector of psychiatry and neurology. Prior to MapLight, she was the Commercial Strategy Advisor at Karuna Therapeutics, where she spearheaded the commercial capabilities for the launch of KarXT in schizophrenia and Alzheimer's disease psychosis.
Charmaine's impressive career includes commercial strategy and execution for 10 product launches in the US and globally for CNS indications.
In this episode, we’ll dive into the resurgence of interest in neuro and CNS disorders, the importance of involving commercial teams early in development, and the challenges and rewards of bringing new treatments to market.
Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of speaking with Laurent Audoly. Laurent is the co-founder and CEO of PriveBio, a precision medicine biotech focused on tackling metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases. Having had roles at Pfizer, Merck, Kymera Therapeutics, and more, Laurent has been instrumental in bringing several novel medicines to market, including 9 through IND and helping 100’s of thousands of patients. He has also successfully led multiple biotech startups. Join us as we delve into Laurent's journey, the challenges he has faced, and his vision for the future of PriveBio and the biotech industry. Enjoy and stay tuned.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Ravneesh Sachdev, a seasoned leader in the biotech industry and the currently partner and Head of Business Development at Apple Tree Partners. Ravneesh experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as SVP Head of Business Development at Acceleron, VP Head of Business Development at Sage Therapeutics, VP Business Development at Bioveritav and Executive Director Business Development at Acorda Therapeutics.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of speaking with Laurent Audoly. Laurent is the co-founder and CEO of PriveBio, a precision medicine biotech focused on tackling metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases. Having had roles at Pfizer, Merck, Kymera Therapeutics, and more, Laurent has been instrumental in bringing several novel medicines to market, including 9 through IND and helping 100’s of thousands of patients. He has also successfully led multiple biotech startups. Join us as we delve into Laurent's journey, the challenges he has faced, and his vision for the future of PriveBio and the biotech industry. Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We're thrilled to welcome Doug Love, the dynamic President and Chief Executive Officer of Annexon Biosciences. With a storied career that spans over two decades in biotech, Douglas brings a wealth of experience from his transformative roles at companies like Elan Pharmaceuticals and Genentech.
At Annexon, he's at the helm of pioneering treatments for classical complement-mediated disorders, driving forward innovations that promise to change the lives of patients around the globe.
Join us as Douglas shares his journey through the biotech landscape, the challenges and achievements of leading Annexon, and his vision for the future of medical treatments.
Enjoy and stay tuned.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Amit Kumar, a seasoned leader in the biotech industry and the current CEO & Chairman of Anixa Biosciences. Amit's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of CombiMatrix, a key player in molecular diagnostics, as well as GFF, and is also the Executive Chairman and co-founder of Actym Therapeutics, a company advancing immune oncology treatments.
Now, at the helm of Anixa Biosciences, Amit is focused on addressing some of the most critical unmet needs in oncology. Under his leadership, the company is advancing cutting-edge therapies and vaccines aimed at tackling cancer, including innovative approaches in immunotherapy and vaccine development.
Amit’s deep expertise, from startups to larger biotech companies, gives him a unique perspective on how to steer innovative science towards tangible clinical outcomes. We're excited to dive into his journey, the challenges and successes along the way, and what's next for Anixa and the broader biotech space.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. With nearly three decades of experience in biopharmaceutical development and manufacturing, Daniel's career spans both major pharmaceutical companies and innovative biotech firms.
Prior to joining Vedanta, he held senior leadership roles at organizations like ContraFect Corporation, Merck Sharp Dohme Biologics, and Nuvelo Inc., where he contributed to advancing various drug candidates and therapeutic approaches.
At Vedanta, Daniel is leading the charge in developing microbiome-based therapies to address immune-mediated and infectious diseases. His deep expertise in operations management and passion for team building have played a crucial role in shaping Vedanta's distinctive culture and advancing its mission.
In this episode, we’ll explore Daniel’s professional journey, the ground-breaking work at Vedanta, the culture he has helped cultivate, and the opportunities and challenges facing the biotech industry.
Welcome back to another episode of The BioHub!
Today, we’re thrilled to have Dr. Chris Haqq, Chief Medical Officer and Head of Research & Development at Elicio Therapeutics, join us.
Chris is an expert in immuno-oncology with over 20 years of experience in the biotech industry. He has a remarkable track record in leading innovative therapies from concept to clinical stages, including his pivotal role in developing groundbreaking T cell therapies at Atara Biotherapeutics.
In this episode, we’ll explore Elicio’s unique approach to cancer immunotherapy, Chris’s insights on the current biotech landscape, and what it takes to lead in such a challenging field.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We’re thrilled to have Martin Taylor, Senior Associate at F-Prime Capital. With a strong background in molecular biology and DNA research, Martin transitioned from the lab to venture capital, where he now helps identify and support innovative biotech companies. In this episode, we’ll explore Martin’s journey, his role at F-Prime, and his insights into the future of biotech. Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We have an extraordinary guest, Angelo Stracquatanio, the Co-founder and CEO of Apprentice.io. Angelo is a visionary in the life sciences industry, leading the world's first cloud-based, manufacturing execution system for life sciences.
With over $200M raised from leading VC funds and being ranked #60 fastest-growing software company on the Inc 5000, Apprentice.io is revolutionizing the industry with its innovative solutions.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We have the honor of hosting TJ Cradick, a pioneering leader in CRISPR technology.
TJ is currently focused on CRISPR consulting and advising new gene-editing companies. He was previously the Chief Scientific Officer at Excision BioTherapeutics, where he led the development of CRISPR-based therapies for viral diseases. Before that, TJ was the 2nd US employee and Head of Genome editing at CRISPR Therapeutics and played a crucial role in the company's growth to a clinical-stage biotech.
Having been in the space since 2000, we’ve got so much to cover. we'll be exploring TJ's journey, the challenges and triumphs of developing CRISPR technology, and the future of genome editing.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
we have an incredible episode lined up with a phenomenal guest, Raphael Ognar! Raphael is the President & CEO, and Co-Founder of NKILT Therapeutics, a biotech company developing innovative cell therapies to target leukemias and solid tumors. With over 25 years in the pharma and biotech industries, Raphael has a wealth of experience in oncology, hematology, and cell therapy.
We'll explore the origin of NKILT, how Raphael found the right partners, and the challenges of securing funding for early-stage biotechs. He'll also share his journey at companies like Celgene and BMS, how he handles pressure, and his decision-making process as a CEO.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
we have the pleasure of hosting David Slack, CEO of Impilo Therapeutics. With over 30 years of experience in the biopharmaceutical industry, David has a proven track record in creating value for companies and investors through strategic partnerships and innovative financing transactions.
David’s impressive career includes leadership roles at public and private biotech firms, as well as major pharmaceutical companies. He played a pivotal role in the merger of Cend Therapeutics with Caladrius Biosciences to form Lisata Therapeutics, and later co-founded Impilo Therapeutics to focus on nucleic acid-based medicine for treating solid tumor cancers.
In this episode, we'll explore David's journey from R&D to business development, the challenges and opportunities in the biotech industry, and the exciting future of Impilo Therapeutics.
Enjoy and stay tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Today, we have a special guest, Jerry McLaughlin, CEO of Life Biosciences. With over 30 years in the biopharmaceutical industry, Jerry has been instrumental in the development and commercialization of more than a dozen FDA-approved drugs. His impressive career started at Merck, and went on to leading roles at Endo, Neos Therapeutics, AgeneBio, and NuPathe. Life Biosciences is dedicated to extending healthy human lifespan by targeting the biological causes of aging. In this episode, we'll explore Jerry's journey from big pharma to biotech startups, his path to becoming a CEO, and the innovative work at Life Biosciences. Enjoy and stay Tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We're thrilled to have Dr. Arjun Goyal!
Arjun is the Co-Founder and Managing Director of Vida Ventures, a leading life sciences venture capital firm with approximately $2 billion under management.
He serves on the boards of companies like Scorpion Therapeutics and Quanta Therapeutics, and has played key roles in several high-profile investments and acquisitions.
We'll dive into Arjun's journey from physician to investor, the story behind Vida Ventures, and what they look for in executives and new company investments. He'll also share insights into current market trends, his decision-making processes, and what sets his mindset apart.
It's an absolute pleasure to welcome Dr. Arjun Goyal!
Enjoy and stay tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We’re excited to host Jason Lettmann, the CEO of ALX Oncology. Jason brings a wealth of experience from his roles as General Partner at Lightstone Ventures and CEO of Promedior Inc., where he led the company to a successful acquisition by Roche. With over a decade of leadership in biotech and venture capital, Jason is now steering ALX Oncology towards groundbreaking advancements in immuno-oncology.
Join us as we dive into Jason's journey, the challenges and successes of ALX Oncology, and their innovative approach to cancer treatment. Welcome to the show, Jason!
Enjoy and stay tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
Today, we have an exceptional guest joining us, Dr. Stella Vnook! Stella is a seasoned biopharmaceutical executive with over 25 years of experience driving transformational change in the industry. She has a remarkable track record of building and managing successful startups, from early-stage R&D through to commercialization. As the CEO of Likarda Biotech and the founder of multiple companies, including OralBioLife, Dialysis Biosciences, and ACG Group, Stella is a true innovator in the biotech space.
In this episode, we’ll explore Stella’s journey, her insights on building successful biotech startups, and her unique approach to hiring first-time CEOs. We’ll also discuss her experiences with gender dynamics in the industry, managing risks in smaller biotech firms, and the importance of diversity and inclusion.
Stella will share her thoughts on the future of cell therapies and the legacy she hopes to leave in the biotech world. It’s an absolute pleasure to welcome Dr. Stella Vnook!
Enjoy and stay tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
Today, we're super excited to welcome a phenomenal guest, Nicole Lambert!
Nicole is a business leader with over two decades of experience at Myriad Genetics, where she played a pivotal role in advancing genetic testing and precision medicine. Recently, she transitioned from her role as Chief Operating Officer to focus on new professional opportunities and continues her impactful work as a senior advisor and board member of Arcus Biosciences.
I first met Nicole when she messaged me on LinkedIn, exploring board roles, and I had the pleasure of placing her on Arcus Biosciences' board. We're diving into some fascinating topics today! We'll explore Nicole's journey at Myriad, how she stayed motivated, her personal connection to genetic testing, and the challenges and successes she faced in her career.
Nicole will also share her insights on handling burnout, the role of women in biotech, and the future of healthcare.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
Today, we’re honored to have Dr. David Mazzo with us!
David is the President and CEO of Lisata Therapeutics, a company dedicated to developing innovative therapies for advanced solid tumors and other major diseases. With a career spanning over 40 years in the pharmaceutical industry, we have so much to discuss.
We'll dive into David's journey, the evolution of Lisata following the merger with Caladrius Biosciences and Cend Therapeutics, and their lead product candidate. He'll also share insights on making tough decisions, fostering a dynamic company culture, and the future of oncology treatment.
It's an absolute pleasure to welcome Dr. David Mazzo!
Enjoy and stay tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
Joining us today is Rob Etherington, CEO of Clene Nanomedicine.
Rob brings over 30 years of experience in pharma, including 8 years at Parke-Davis, 13 years at Actelion—where he was part of the team that took the company public—and now, 11 years leading Clene.
At Clene, he's at the forefront of using nanotechnology to tackle neurodegenerative diseases.
Enjoy and stay tuned!
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We’re excited to host Dr. Christina Trojel-Hansen. Christina is a leading figure in biotech, having co-founded several innovative companies, including Tune Therapeutics, which specializes in gene regulation technology, Oscine Therapeutics, which is making significant advancements in CNS cell therapy, and Pretzel Therapeutics, focused on mitochondrial diseases.
As an Entrepreneur in Residence at ARCH Venture Partners, Christina has played a pivotal role in transforming early-stage ideas into viable medical breakthroughs.
Christina’s strategic insight has also been instrumental in securing major Series A investments for biotech innovators like Adcendo and Stipe Therapeutics.
Her leadership and vision have earned her a place among the Top 10 Inspirational Women in Nordic Life Science and the Endpoints 20 under 40, highlighting her as a future leader in biotech.
Join us as we delve into her story of entrepreneurship, innovation, and leadership in the biotech landscape.
Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We're super excited to welcome a phenomenal guest, Michael Parini! Michael is the CEO of Spur Therapeutics, a clinical-stage biotechnology company dedicated to developing transformative gene therapies for chronic debilitating diseases. With over 20 years of experience as a senior executive in the biopharma and biotech industries, Michael has held key roles at Vertex and Pfizer before joining Spur. In this episode, we’ll dive into the exciting rebrand of Freeline now spur, what inspired Michael to join the company, and how Spur is approaching gene therapy in innovative ways. We’ll also discuss the challenges of reshaping the company, maintaining stability and culture, the importance of diversity and inclusion, and how Freeline is making a difference for patients. Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We're super excited to welcome a phenomenal guest, Matthew Shaulis! Matthew is the Chief Commercial Officer and US President of Hansa Biopharma. With over 20 years of experience in the pharmaceutical industry, he's held top executive roles at giants like Pfizer and Teva. Now, he's leading the charge at Hansa, bringing groundbreaking treatments for rare immunological diseases to the US. We're diving into some fascinating topics today! We'll explore the incredible growth of Hansa Biopharma, what makes it stand out, and the unique challenges and opportunities in the biotech world. Matthew will share his insights on making tough business decisions, navigating the unpredictable biotech landscape, and the exciting milestones ahead for Hansa. Plus, we'll get a peek into his personal journey and what fuels his impressive career.
Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We were thrilled to welcome Someit Sidhu, an inspiring entrepreneur who has made significant strides in the biotech industry.
Someit is the founder of multiple groundbreaking companies, including Zura Bio, where he successfully led the company through a strategic SPAC merger and a notable public offering.
He also founded Izana Bioscience, which he successfully sold to Roivant Sciences, and his first venture, Pathios Therapeutics. Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Today we welcome a true visionary with the co-founder and CEO of Simbiosys Leading the charge of such an innovative company, which is revolutionizing cancer care by blending artificial intelligence with personalized medicine.
I'm thrilled about the insights and stories we're about to uncover as we welcome Tushar Pandey to the show. Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have Barbara Ryan who has over 40 years in Healthcare capital Markets with 31 years on wall street! She currently serves on 6 biotech boards including Indivior and MINK. She has raised over $1.5B for emerging biopharma companies in IPOs, follow-ons and convertible debt transactions. She is also the Founder of Fabulous Pharma Females, a non-profit dedicated to advancing and mentoring women in biopharma. Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We have Owen Hughes who has spent the last 25 years in healthcare as both an operator and investor.
Currently the CEO of XOMA, former CEO of Sail Bio and former CEO and co-founder of Cullinan Oncology, who did $380M in private raises before a $250M IPO in 2021. Prior to Cullinan he served as CBO for Intarcia Therapeutics.
He started his career on wall street, initially in equity research at Morgan Stanley before transitioning to buyside, where he managed public and private healthcare investments for Brookside Capital.
Hewas also the Chairman of Radius Health before it’s sale of 890 million dollars, Lead independent director for Translate bio before it’s sale of $3.2B and is currently Chairman of Ikena Oncology.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Frank Watanabe! CEO and President of Arcutis Therapeutics, where he has been since it's founding in 2016. During that time they have done multiple successful raises, an $160M IPO and have developed more than 2 FDA approved products with a 3rd being reviewed. Before this he was COO and co-founder of Kanan Therapeutics and VP of strategy and corporate development at Kythera. He also held numerous exec roles throughout his time at Amgen and Eli Lilly and was involved in the development and marketing of 3 approved drugs. He was also a commissioned officer in the US Navy reserves for 25 years. Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Paul Peter Tak! CEO and President of Candel Therapeutics
From a professorship in his native Netherlands to the SVP, Chief Immunology Officer, and global development leader at GSK, and from leading small biotechs such as Tempero and Kintai to entering the venture world as a Flagship partner.
Now, he is the CEO and President of Candel Therapeutics – a promising clinical immunotherapy company in the fight against cancer.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
40 years of experience across biotech and pharma! 6 years as CEO of Ipsen, where he currently serves as Chairman.
He led the successful sale of Cincor Pharma for 1.8 Billion dollars to Astrazeneca and the sale of Corvidia to Novo Nordisk for 2.1 billion dollars.
Now he serves as the CEO of Abivax, who just completed the largest ever NASDAQ IPO for a French biotech!
Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Dr Stanley Lewis the CEO and founder of A28 Therapeutics. With a remarkable 25-year career in life sciences across clinical research, and drug development, he is a true leader in the field. Formerly Chief Medical Officer at Ansun Biopharma, he successfully led late-stage trials, helped secure a $100 million Series B, and contributed to strategic in-licensing efforts. In 2021, he founded A28, aiming to revolutionize global cancer care. Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Dr. Chris Mirabelli, who has 40 years of experience across Biotech and Pharma. Currently serving as Chairman of Leap Therapeutics, where he was the CEO from its founding in 2015 until 2020. A managing Director of HealthCare ventures, where since joining in 2000, they have raised 1 billion dollars across 4 funds and has been involved in over 15 investments leading to successful exits. Before his VC ventures, he was the CEO and Chairman of LeukoSite from its inception in 1993 until its acquisition by Millennium in 1999. Before that he was a co-founder of Ionis Pharma who today sit at a 7-billion-dollar market cap and a workforce of 1,000 employees. Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. This week we welcome Dr. Michael Tusche, who has 20 years of experience spanning, science, wall street and biotech. He was employee number one and co-CEO of Treadwell Therapeutics where they raised $118M, advanced 3 assets into the clinic and expanded the team to 50+. Enjoy and stay tuned.
En liten tjänst av I'm With Friends. Finns även på engelska.